FarrukhTAwanMD

Hematology • Dallas, TX

Hematologic Oncology

Associate Professor of Internal Medicine

Join to view full profile

Dr. Awan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Awan's full profile

Already have an account?

Office
6201 Harry Hines Blvd Mail Code 8565
Dallas, TX 75390
Phone+1 214-645-4673

Fax+1 214-645-2661

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2006 - 2009
UPMC Medical EducationResidency, Internal Medicine, 2003 - 2006
Aga Khan Medical CollegeClass of 2001

Certifications & Licensure

TX State Medical License 2018 - 2025
OH State Medical License 2006 - 2019
GA State Medical License 2009 - 2014

Clinical Trials

Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia Start of enrollment: 2010 Sep 01
Completed
Phase 1
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2011 Nov 02
Active, not recruiting
Phase 2
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2016 Jan 12
Active, not recruiting
Phase 2
Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL Start of enrollment: 2015 Nov 09
Terminated
Phase 1, Phase 2
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) Start of enrollment: 2020 Nov 18
Suspended
Phase 1, Phase 2
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) Start of enrollment: 2019 Jul 22
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2017 Nov 27
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
DALY II USA/ MB-CART2019.1 for DLBCL Start of enrollment: 2021 May 25
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

96 citations
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody
Farrukh T. Awan, Rosa Lapalombella, Rossana Trotta, Jonathan P. Butchar, Bo Yu
Blood. 2010-02-11
4 citations
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
Madiha Iqbal, Deepa Jagadeesh, Julio Chavez, Arushi Khurana, Allison Rosenthal
Bone Marrow Transplantation. 2024-02-01
31 citations
Representation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trials.
Janice M. Bonsu, Lawrence Charles, Avirup Guha, Farrukh T. Awan, Jennifer A. Woyach
Circulation. 2019-05-28

Abstracts/Posters

Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
Farrukh T. Awan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
Farrukh T Awan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy
Farrukh T. Awan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Farrukh T. Awan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic Leukemia
Farrukh T. Awan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
Farrukh T. Awan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting
Farrukh T. Awan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Press Mentions

The IntersectionFebruary 1st, 2022
Lymphoma Research Foundation to Host Nationwide Virtual RallyApril 28th, 2020
Questions with BTK Inhibitors and Anti-CD20 Combos Require Further Study in CLLApril 10th, 2020
Join now to see all